News & Articles

The agreement is part of preparations for GMP production of material for the first clinical study of CG01

New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus

Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021

Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method

The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

Connecting the scientific community with two new online content-packed events

Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

The high-throughput system enables laboratories to double or even triple their testing capacity

Join us on Tuesday, August 11, to learn about a novel serological platform used for COVID-19 testing

Join us on Monday, August 17, to discover solutions for your laboratory's SARS-CoV-2 testing

BLENREP is the fifth major medicine approval for GSK in 2020